The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 5.14 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.53 — no flag raisedOK
- Earnings quality 80/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as QIAGEN N.V. reports it. History and quarterly detail are in the app.
- Consumables and related revenues$1.9B
- Diagnostic solutions$803.1M
- Sample technologies$661.3M
- PCR/Nucleic acid amplification$309.0M
- Genomics/NGS$241.8M
Latest filings
- 6-K · Company announcement (foreign filer)2026-08-07
- 6-K · Company announcement (foreign filer)2026-08-07
- 6-K · Company announcement (foreign filer)2026-08-07
- 6-K · Company announcement (foreign filer)2026-05-08
- 6-K · Company announcement (foreign filer)2026-05-08
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about QIAGEN N.V., every answer cited to the official filings🔒
- The Intelligence Brief — added when QIAGEN N.V.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.